Sopherion Therapeutics, LLC Announces Publication Of Phase I/II Myocet(R) (Nonpegylat

[News]

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the January 1 issue of Clinical Cancer Research. The study was supported by a grant from Roche and was conducted by the Spanish Breast Cancer Cooperative Group (SOLTI).

More... (http://www.medicalnewstoday.com/articles/138059.php)